Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Mallinckrodt
Colorcon
Medtronic
Merck

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR ATRALIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Atralin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00603772 ↗ Clinical Evaluation of the Photoallergy Potential of Atralin Gel Completed Coria Laboratories, Ltd. Phase 1 2008-01-01 To assess the potential of tretinoin gel 0.05% and its vehicle to produce photoallergic reactions, measured as skin reactions following induction and challenge.
NCT00604032 ↗ Study to Determine the Phototoxity of Atralin (Tretinoin) Gel, 0.05% Completed Coria Laboratories, Ltd. Phase 1 2008-01-01 To assess the potential of tretnoin gel 0.05% to produce phototoxic reactions, measured as skin reactions 24 and 48 hours after UV radiation of drug on skin.
NCT00621218 ↗ A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea Completed Coria Laboratories, Ltd. Phase 2 2008-02-01 To compare the efficacy and safety of tretinoin gel 0.05% to its vehicle when dosed once or twice daily in female subjects with rosacea.
NCT01125930 ↗ Atralin Gel for the Treatment of Rosacea Terminated Bausch Health Americas, Inc. Phase 3 2010-05-01 Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. We think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. Tretinoin is a topical medication that is known to improve photodamage. We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR).
NCT01125930 ↗ Atralin Gel for the Treatment of Rosacea Terminated Valeant Pharmaceuticals International, Inc. Phase 3 2010-05-01 Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. We think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. Tretinoin is a topical medication that is known to improve photodamage. We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR).
NCT01125930 ↗ Atralin Gel for the Treatment of Rosacea Terminated Lisa E. Maier Phase 3 2010-05-01 Erythematotelangiectatic rosacea is a type of rosacea that causes a red face often with frequent flushing, topical sensitivity and prominent blood vessels. We think that long term damage to skin from the sun (photodamage) may play a role in causing this type of rosacea. Tretinoin is a topical medication that is known to improve photodamage. We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR).
NCT01283464 ↗ Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles Completed Johns Hopkins University Phase 2 2010-11-01 The purpose of this study is to assess the comparative efficacy of retinol 1.0% and tretinoin 0.02% in minimizing wrinkles, discoloration, roughness, and other signs of moderate to severe photodamage. Our hypothesis is that both products will be of comparable benefit.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Atralin

Condition Name

Condition Name for Atralin
Intervention Trials
Healthy 2
Rosacea 2
Acne Vulgaris 1
Photodamaged Skin 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Atralin
Intervention Trials
Rosacea 2
Dermatitis, Photoallergic 1
Acne Vulgaris 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Atralin

Trials by Country

Trials by Country for Atralin
Location Trials
United States 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Atralin
Location Trials
North Carolina 2
New York 1
Maryland 1
Michigan 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Atralin

Clinical Trial Phase

Clinical Trial Phase for Atralin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Atralin
Clinical Trial Phase Trials
Completed 4
Terminated 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Atralin

Sponsor Name

Sponsor Name for Atralin
Sponsor Trials
Coria Laboratories, Ltd. 3
Bausch Health Americas, Inc. 1
Valeant Pharmaceuticals International, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Atralin
Sponsor Trials
Industry 5
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Medtronic
McKesson
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.